Suppr超能文献

肝移植受者正常血清转氨酶水平范围

Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients.

作者信息

Siddiqui Mohammad Bilal, Patel Samarth, Bhati Chandra, Reichman Trevor, Williams Kenyada, Driscoll Carolyn, Liptrap Erika, Rinella Mary E, Sterling Richard K, Siddiqui M Shadab

机构信息

Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, Virginia.

Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, Virginia.

出版信息

Transplant Proc. 2019 Jul-Aug;51(6):1895-1901. doi: 10.1016/j.transproceed.2019.04.062.

Abstract

UNLABELLED

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are used to monitor liver transplant recipients (LTR) but the reference range and context of its use is not well defined. We aimed to determine the healthy ranges in LTR without chronic liver disease.

METHODS

One hundred and three LTR without chronic liver disease based on serology, transient elastography with controlled attenuated parameter, and ultrasound were included. A healthy range of aminotransferases was set to 95th percentile. An updated normal aminotransferase range was used to detect recurrence in post-liver transplantation (LT) with hepatitis C virus (HCV) and nonalcoholic fatty liver disease (NAFLD).

RESULTS

The normal ALT and AST range was 0 to 57 and 0 to 54 IU/L, respectively, in LTR and was not affected by age, sex, obesity, or choice of immunosuppressant. The diagnostic performance of serum ALT and AST to detect recurrence of NAFLD by a controlled attenuated parameter was poor with area under the receiver operating characteristic curve of 0.573 (95% confidence interval 0.493, 0.655; P = .08) and 0.537 (0.456, 0.618; P = .4), respectively. In contrast, the diagnostic performance of ALT and AST to detect recurrence of HCV after LT was 0.906 (0.868, 0.944; P < .001) and 0.925 (0.890, 0.959; P < .001), respectively.

CONCLUSION

The updated aminotransferase range in LTR is higher than the general population and accurate for detecting recurrent HCV, but not NAFLD.

摘要

未标注

丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)用于监测肝移植受者(LTR),但其参考范围及使用背景尚未明确界定。我们旨在确定无慢性肝病的肝移植受者的健康范围。

方法

纳入103例基于血清学、受控衰减参数瞬时弹性成像及超声检查无慢性肝病的肝移植受者。将转氨酶的健康范围设定为第95百分位数。采用更新后的正常转氨酶范围检测丙型肝炎病毒(HCV)和非酒精性脂肪性肝病(NAFLD)肝移植术后的复发情况。

结果

肝移植受者中正常ALT和AST范围分别为0至57 IU/L和0至54 IU/L,且不受年龄、性别、肥胖或免疫抑制剂选择的影响。血清ALT和AST通过受控衰减参数检测NAFLD复发的诊断性能较差,受试者操作特征曲线下面积分别为0.573(95%置信区间0.493, 0.655;P = 0.08)和0.537(0.456, 0.618;P = 0.4)。相比之下,ALT和AST检测肝移植术后HCV复发的诊断性能分别为0.906(0.868, 0.944;P < 0.001)和0.925(0.890, 0.959;P < 0.001)。

结论

肝移植受者更新后的转氨酶范围高于一般人群,对检测复发性HCV准确,但对NAFLD不准确。

相似文献

1
Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients.肝移植受者正常血清转氨酶水平范围
Transplant Proc. 2019 Jul-Aug;51(6):1895-1901. doi: 10.1016/j.transproceed.2019.04.062.

本文引用的文献

2
The Care of the Postliver Transplant Patient.肝移植术后患者的护理
J Clin Gastroenterol. 2017 Sep;51(8):683-692. doi: 10.1097/MCG.0000000000000886.
3
Cholestatic Liver Diseases After Liver Transplant.肝移植后的胆汁淤积性肝病
Clin Liver Dis. 2017 May;21(2):403-420. doi: 10.1016/j.cld.2016.12.011.
8
From immunosuppression to tolerance.从免疫抑制到免疫耐受。
J Hepatol. 2015 Apr;62(1 Suppl):S170-85. doi: 10.1016/j.jhep.2015.02.042.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验